NCT00456027 - Safety of Diamyd® in Patients With LADA (Latent Autoimmune Diabetes in Adult) | Biotech Hunter

Enrollment

160

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

March 31, 2008

Study Completion Date

April 30, 2008

Conditions

Latent Autoimmune Diabetes in Adult (LADA)

Interventions

DRUG

rhGAD65 formulated in Alhydrogel® (Diamyd®)

20 micrograms of rhGAD65 formulated in Alhydrogel® administered subcutaneously twice 4 weeks apart

Trial Locations (17)

Alingsås Hospital, Alingsås

Falu Hospital, Falun

Capio Lundby Hospital, Gothenburg

Härnösand Hospital, Härnösand

Helsingborg Hospital, Helsingborg

Karlstad Central Hospital, Karlstad

Central Hospital, Kristianstad, Kristianstad

Sunderby Hospital, Luleå

University Hospital MAS, Malmo

Vrinnevi Hospital, Norrköping

Odensala Health Clinic, Östersund

Skellefteå Hospital, Skellefteå

S:t Göran Hospital, Stockholm

Stockholm South General Hospital, Stockholm

Norrlands University Hospital, Umeå

Uppsala University Hospital, Uppsala

Växjö Central Hospital, Vaxjo